Sotera Health(SHC) ZACKS·2025-02-27 15:36Core Insights - Sotera Health Company reported revenue of $290.2 million for the quarter ended December 2024, a decrease of 6.5% compared to the same period last year [1] - The earnings per share (EPS) for the quarter was $0.21, down from $0.26 in the year-ago quarter, aligning with the consensus EPS estimate [1] - The reported revenue fell short of the Zacks Consensus Estimate of $291.56 million, resulting in a surprise of -0.46% [1] Financial Performance - Net Revenues for Sterigenics were reported at $179.43 million, slightly below the estimated $182.82 million, but showed a year-over-year increase of 4.2% [4] - Nelson Labs reported Net Revenues of $53.98 million, which was lower than the estimated $55.49 million, reflecting a year-over-year decline of 7.3% [4] - Nordion's Net Revenues were $56.79 million, exceeding the average estimate of $53.25 million, but represented a significant year-over-year decrease of 28.9% [4] Segment Income - Segment Income for Sterigenics was $99.59 million, slightly below the average estimate of $101.07 million [4] - Nelson Labs achieved Segment Income of $18.07 million, which was above the average estimate of $17.87 million [4] - Nordion's Segment Income was reported at $35.28 million, surpassing the average estimate of $33.55 million [4] Stock Performance - Shares of Sotera Health have returned -0.3% over the past month, compared to a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]